Christian Plaza

Partner
Full contact info

I work with clients in the life sciences and medtech industries on their financings and strategic transactions.

Experience

PhaseBio Pharmaceuticals – $46 Million IPO

October 17, 2018

Cooley advised PhaseBio Pharmaceuticals, Inc. on its $46 million initial public offering of 9,200,000 shares of common stock. The underwriters have a 30-day option to purchase an additional 1,380,000 shares. Partners Darren DeStefano and Christian Plaza led the Cooley team advising PhaseBio Pharmaceuticals.

Citigroup, Cowen and Stifel acted as the joint-book-running managers for the offering. Needham & Company acted as co-manager for the offering.

PhaseBio is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for the treatment of serious orphan diseases, with an initial focus on cardiopulmonary disorders. The company’s shares now trade on the Nasdaq Global Market under the symbol “PHAS.”

Related contacts

Darren DeStefano
Partner, Reston
Christian Plaza
Partner, Reston
Madison Jones
Partner, Washington, DC

Related Practices & Industries

Entasis Therapeutics – $75 Million IPO

October 3, 2018

Cooley advised Entasis Therapeutics on its $75 million initial public offering of 5,000,000 shares of common stock. Partners Christian Plaza, Brent Siler and Brian Leaf led the Cooley team advising Entasis.

Credit Suisse and BMO Capital Markets acted as joint book-running managers for the offering. SunTrust Robinson Humphrey and Wedbush Securities acted as co-managers.

Entasis Therapeutics, which now trades on the Nasdaq Global Market as “ETTX,” is developing a portfolio of innovative product candidates to treat serious gram-negative multi-drug resistant bacterial infections.

Related contacts

Christian Plaza
Partner, Reston
Jaime L. Chase
Partner, Washington, DC
Katie Kazem
Partner, Reston
Darah Protas
Partner, Washington, DC
Asheley Walker
Associate, Washington, DC

Related Practices & Industries

Autolus – $173 Million IPO

June 21, 2018

Cooley advised Autolus Therapeutics on its $172.5 million initial public offering of 10,147,059 American Depositary Shares, which includes the full exercise of the underwriters’ option to purchase additional shares.

Read more

Related contacts

Christian Plaza
Partner, Reston
Darren DeStefano
Partner, Reston
Courtney Thorne
Partner, London
Tom Goodman
Partner, London
Katie Kazem
Partner, Reston
Mark Jones
Associate, London
William DuVal
Special Counsel, Reston
Paula Fleckenstein
Associate, Reston

Related Practices & Industries

Sucampo Sells to Mallinckrodt for $1.2 Billion

December 27, 2017

Cooley advised global biopharmaceutical company Sucampo on its acquisition by Mallinckrodt in an all-cash transaction valued at $1.2 billion. The transaction will allow for the continued production of Sucampo’s leading global product for treating constipation, Amitiza, and also fuel the development of two phase 3 pharmaceuticals to treat rare diseases Niemann-Pick Type C (NPC) and Familial Adenomatous Polyposis (FAP). Barbara Borden, partner and co-chair of Cooley’s M&A practice, and partner Christian Plaza, led the team advising Sucampo on its sale.

Read more

Related contacts

Barbara Borden
Senior Counsel, San Diego
Christian Plaza
Partner, Reston
Matthew Schwee
Partner, Reston
Andrew Gunther
Associate, New York
Stephanie Gentile
Partner, New York
David Walsh
Senior Counsel, Reston
Michael Tollini
Partner, Washington, DC
Rowook Park
Partner, San Diego
Sharon Connaughton
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC

Related Practices & Industries

Cardioxyl Pharmaceuticals sale to Bristol-Myers Squibb

November 5, 2015

Cooley is advising Cardioxyl Pharmaceuticals on its sale to Bristol-Myers Squibb. Under the terms of the agreement, BMS will acquire all of the issued and outstanding capital stock of Cardioxyl for upfront and near-term milestone payments of up to $300 million and potential additional milestone payments of up to $1.78 billion. The transaction is expected to close before year end.

The acquisition strengthens BMS's focus on heart failure and gives the company full rights to Cardioxyl's CXL-1427, a novel drug that releases nitroxyl – a molecule that has demonstrated positive effects on heart muscle and vascular function. The drug is in development for acute decompensated heart failure.

Cardioxyl, based in Chapel Hill, North Carolina, is a privately held, clinical stage biopharmaceutical company focused on the discovery and development of new classes of safe and effective therapies for the treatment of cardiovascular disease.

Related contacts

Barbara Borden
Senior Counsel, San Diego
Christian Plaza
Partner, Reston
Kenneth Krisko
Partner, Reston
Todd Gluth
Partner, San Diego
Natasha Leskovsek
Of Counsel, Washington, DC
Ben Beerle
Partner, San Francisco

Related Practices & Industries

View more

Admissions and credentials

Maryland

Massachusetts

Virginia

Memberships and affiliations

American Bar Association (ABA)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.